Chelsie Derman

A recent study suggests fibromyalgia has little effect on polysomnographic indicators of obstructive sleep apnea-hypopnea syndrome.

A study examines why patients with inflammatory arthritis might seek emergency department care over ambulatory care.

At EULAR, Tonix Pharmaceuticals presented the phase 3 RESILIENT trial which met the primary endpoint of TNX-102 SL reducing daily pain intensity.

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

Some of the risk factors for RA-interstitial lung disease include male sex, older age, and smoking history, a study found.

A new study found an indirect effect of RA on frailty index through inflammatory cytokines.

Exactly half of the sample had previously read or applied ≥ 1 Clinical Practice Guideline in the field of fibromyalgia.

In a new study, 16% of patients with RA and 22% with PsA had sleeping issues during the last week.

As the severity of rheumatoid arthritis disease activity increases, so does the prevalence of depression, a new study found.

Age, chronic comorbidities, and COVID-19 vaccination status in patients with IMIDs serve as risk factors for severe COVID-19 outcomes.

Combining algorithms SCORE2 and QRISK3 created the best predictive model to predict the cardiovascular risk for patients with PsA.

When the serum cotinine levels were below -2.756 ng/mL, each 1 ng/mL increase in log-2-transformed serum cotinine levels increased the RA risk by 16.3%.

A new study found febuxostat can effectively delay the progression of kidney function deterioration in patients with gout.

Treatment-resistant depression with intranasal esketamine was linked to improvements in major depressive disorder (MDD) symptoms and fibromyalgia pain in a 40-year-old female.

Cardiorespiratory fitness showed the strongest association with gait parameters for women with fibromyalgia.

A new study highlights the importance of daily antioxidant intake for endometriosis-related RA.

Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

An extension study showed upadacitinib 15 mg and 30 mg for rheumatoid arthritis continues to be favorable, with many patients achieving remission.

A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.

A study found MRI treat-to-target strategy does not help bring RA patients to remission, even when also targeting the absence of osteitis alongside clinical remission.

The first guideline for the management of osteoporosis in men provides recommendations for diagnosis, monitoring, and treatment.

A meta-analysis found febuxostat was linked to a greater risk for acute coronary syndrome and atrial fibrillation than allopurinol among Asian patients with and without gout.

Participants with an RA risk had various opinions on preventive measures, from being on board, needing to be swayed by a doctor, and fearing the intervention.

A new study found RA patients with concomitant Sjögren’s disease were more likely to fail TNFi treatment than the treatments of other mode of action biologics and JAKi.

A new study evaluated gender differences in physical functioning, sexual dysfunction, depression, fatigue, pain, and loneliness among RA patients using and not using methotrexate.

Of 1156 participants with chronic musculoskeletal pain, 1073 participants retired at an earlier age. Participants with chronic pain were 1.25 times more likely to stop working.

Aquatic therapy for women with fibromyalgia in Spain is better than land-based therapy for reducing pain levels and improving sleep quality, as seen at the 6-week follow-up.

From 1990 to 2019, the prevalence, incidence, and disability-adjusted life years of gout worldwide increased by 22.4%, 18%, and 22.2%, respectively.